Chapter 1 Industry Overview

1.1 Definition

1.2 Assumptions

1.3 Research Scope

1.4 Market Analysis by Regions

1.4.1 North America Market States and Outlook (2022-2027)

1.4.2 East Asia Market States and Outlook (2022-2027)

1.4.3 Europe Market States and Outlook (2022-2027)

1.4.4 South Asia Market States and Outlook (2022-2027)

1.4.5 Southeast Asia Market States and Outlook (2022-2027)

1.4.6 Middle East Market States and Outlook (2022-2027)

1.4.7 Africa Market States and Outlook (2022-2027)

1.4.8 Oceania Market States and Outlook (2022-2027)

1.4.9 South America Market States and Outlook (2022-2027)

1.5 Global Companion Cancer Diagnostics Market Size Analysis from 2022 to 2027

1.5.1 Global Companion Cancer Diagnostics Market Size Analysis from 2022 to 2027 by Consumption Volume

1.5.2 Global Companion Cancer Diagnostics Market Size Analysis from 2022 to 2027 by Value

1.5.3 Global Companion Cancer Diagnostics Price Trends Analysis from 2022 to 2027

1.6 COVID-19 Outbreak: Companion Cancer Diagnostics Industry Impact

Chapter 2 Global Companion Cancer Diagnostics Competition by Types, Applications, and Top Regions and Countries

2.1 Global Companion Cancer Diagnostics (Volume and Value) by Type

2.1.1 Global Companion Cancer Diagnostics Consumption and Market Share by Type (2016-2021)

2.1.2 Global Companion Cancer Diagnostics Revenue and Market Share by Type (2016-2021)

2.2 Global Companion Cancer Diagnostics (Volume and Value) by Application

2.2.1 Global Companion Cancer Diagnostics Consumption and Market Share by Application (2016-2021)

2.2.2 Global Companion Cancer Diagnostics Revenue and Market Share by Application (2016-2021)

2.3 Global Companion Cancer Diagnostics (Volume and Value) by Regions

2.3.1 Global Companion Cancer Diagnostics Consumption and Market Share by Regions (2016-2021)

2.3.2 Global Companion Cancer Diagnostics Revenue and Market Share by Regions (2016-2021)

Chapter 3 Production Market Analysis

3.1 Global Production Market Analysis

3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

3.1.2 2016-2021 Major Manufacturers Performance and Market Share

3.2 Regional Production Market Analysis

3.2.1 2016-2021 Regional Market Performance and Market Share

3.2.2 North America Market

3.2.3 East Asia Market

3.2.4 Europe Market

3.2.5 South Asia Market

3.2.6 Southeast Asia Market

3.2.7 Middle East Market

3.2.8 Africa Market

3.2.9 Oceania Market

3.2.10 South America Market

3.2.11 Rest of the World Market

Chapter 4 Global Companion Cancer Diagnostics Sales, Consumption, Export, Import by Regions (2016-2021)

4.1 Global Companion Cancer Diagnostics Consumption by Regions (2016-2021)

4.2 North America Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.3 East Asia Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.4 Europe Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.5 South Asia Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.6 Southeast Asia Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.7 Middle East Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.8 Africa Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.9 Oceania Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

4.10 South America Companion Cancer Diagnostics Sales, Consumption, Export, Import (2016-2021)

Chapter 5 North America Companion Cancer Diagnostics Market Analysis

5.1 North America Companion Cancer Diagnostics Consumption and Value Analysis

5.1.1 North America Companion Cancer Diagnostics Market Under COVID-19

5.2 North America Companion Cancer Diagnostics Consumption Volume by Types

5.3 North America Companion Cancer Diagnostics Consumption Structure by Application

5.4 North America Companion Cancer Diagnostics Consumption by Top Countries

5.4.1 United States Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

5.4.2 Canada Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

5.4.3 Mexico Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 6 East Asia Companion Cancer Diagnostics Market Analysis

6.1 East Asia Companion Cancer Diagnostics Consumption and Value Analysis

6.1.1 East Asia Companion Cancer Diagnostics Market Under COVID-19

6.2 East Asia Companion Cancer Diagnostics Consumption Volume by Types

6.3 East Asia Companion Cancer Diagnostics Consumption Structure by Application

6.4 East Asia Companion Cancer Diagnostics Consumption by Top Countries

6.4.1 China Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

6.4.2 Japan Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

6.4.3 South Korea Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 7 Europe Companion Cancer Diagnostics Market Analysis

7.1 Europe Companion Cancer Diagnostics Consumption and Value Analysis

7.1.1 Europe Companion Cancer Diagnostics Market Under COVID-19

7.2 Europe Companion Cancer Diagnostics Consumption Volume by Types

7.3 Europe Companion Cancer Diagnostics Consumption Structure by Application

7.4 Europe Companion Cancer Diagnostics Consumption by Top Countries

7.4.1 Germany Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.2 UK Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.3 France Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.4 Italy Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.5 Russia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.6 Spain Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.7 Netherlands Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.8 Switzerland Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

7.4.9 Poland Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 8 South Asia Companion Cancer Diagnostics Market Analysis

8.1 South Asia Companion Cancer Diagnostics Consumption and Value Analysis

8.1.1 South Asia Companion Cancer Diagnostics Market Under COVID-19

8.2 South Asia Companion Cancer Diagnostics Consumption Volume by Types

8.3 South Asia Companion Cancer Diagnostics Consumption Structure by Application

8.4 South Asia Companion Cancer Diagnostics Consumption by Top Countries

8.4.1 India Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

8.4.2 Pakistan Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

8.4.3 Bangladesh Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 9 Southeast Asia Companion Cancer Diagnostics Market Analysis

9.1 Southeast Asia Companion Cancer Diagnostics Consumption and Value Analysis

9.1.1 Southeast Asia Companion Cancer Diagnostics Market Under COVID-19

9.2 Southeast Asia Companion Cancer Diagnostics Consumption Volume by Types

9.3 Southeast Asia Companion Cancer Diagnostics Consumption Structure by Application

9.4 Southeast Asia Companion Cancer Diagnostics Consumption by Top Countries

9.4.1 Indonesia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.2 Thailand Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.3 Singapore Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.4 Malaysia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.5 Philippines Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.6 Vietnam Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

9.4.7 Myanmar Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 10 Middle East Companion Cancer Diagnostics Market Analysis

10.1 Middle East Companion Cancer Diagnostics Consumption and Value Analysis

10.1.1 Middle East Companion Cancer Diagnostics Market Under COVID-19

10.2 Middle East Companion Cancer Diagnostics Consumption Volume by Types

10.3 Middle East Companion Cancer Diagnostics Consumption Structure by Application

10.4 Middle East Companion Cancer Diagnostics Consumption by Top Countries

10.4.1 Turkey Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.2 Saudi Arabia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.3 Iran Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.4 United Arab Emirates Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.5 Israel Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.6 Iraq Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.7 Qatar Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.8 Kuwait Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

10.4.9 Oman Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 11 Africa Companion Cancer Diagnostics Market Analysis

11.1 Africa Companion Cancer Diagnostics Consumption and Value Analysis

11.1.1 Africa Companion Cancer Diagnostics Market Under COVID-19

11.2 Africa Companion Cancer Diagnostics Consumption Volume by Types

11.3 Africa Companion Cancer Diagnostics Consumption Structure by Application

11.4 Africa Companion Cancer Diagnostics Consumption by Top Countries

11.4.1 Nigeria Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

11.4.2 South Africa Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

11.4.3 Egypt Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

11.4.4 Algeria Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

11.4.5 Morocco Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 12 Oceania Companion Cancer Diagnostics Market Analysis

12.1 Oceania Companion Cancer Diagnostics Consumption and Value Analysis

12.2 Oceania Companion Cancer Diagnostics Consumption Volume by Types

12.3 Oceania Companion Cancer Diagnostics Consumption Structure by Application

12.4 Oceania Companion Cancer Diagnostics Consumption by Top Countries

12.4.1 Australia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

12.4.2 New Zealand Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 13 South America Companion Cancer Diagnostics Market Analysis

13.1 South America Companion Cancer Diagnostics Consumption and Value Analysis

13.1.1 South America Companion Cancer Diagnostics Market Under COVID-19

13.2 South America Companion Cancer Diagnostics Consumption Volume by Types

13.3 South America Companion Cancer Diagnostics Consumption Structure by Application

13.4 South America Companion Cancer Diagnostics Consumption Volume by Major Countries

13.4.1 Brazil Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.2 Argentina Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.3 Columbia Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.4 Chile Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.5 Venezuela Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.6 Peru Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.7 Puerto Rico Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

13.4.8 Ecuador Companion Cancer Diagnostics Consumption Volume from 2016 to 2021

Chapter 14 Company Profiles and Key Figures in Companion Cancer Diagnostics Business

14.1 F. Hoffmann-La Roche

14.1.1 F. Hoffmann-La Roche Company Profile

14.1.2 F. Hoffmann-La Roche Companion Cancer Diagnostics Product Specification

14.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.2 Myriad Genetics

14.2.1 Myriad Genetics Company Profile

14.2.2 Myriad Genetics Companion Cancer Diagnostics Product Specification

14.2.3 Myriad Genetics Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.3 Abbott Laboratories

14.3.1 Abbott Laboratories Company Profile

14.3.2 Abbott Laboratories Companion Cancer Diagnostics Product Specification

14.3.3 Abbott Laboratories Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.4 Agilent Technologies

14.4.1 Agilent Technologies Company Profile

14.4.2 Agilent Technologies Companion Cancer Diagnostics Product Specification

14.4.3 Agilent Technologies Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.5 bioMrieuxSA

14.5.1 bioMrieuxSA Company Profile

14.5.2 bioMrieuxSA Companion Cancer Diagnostics Product Specification

14.5.3 bioMrieuxSA Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.6 QIAGEN

14.6.1 QIAGEN Company Profile

14.6.2 QIAGEN Companion Cancer Diagnostics Product Specification

14.6.3 QIAGEN Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.7 Danaher Corporation

14.7.1 Danaher Corporation Company Profile

14.7.2 Danaher Corporation Companion Cancer Diagnostics Product Specification

14.7.3 Danaher Corporation Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.8 Almac Group

14.8.1 Almac Group Company Profile

14.8.2 Almac Group Companion Cancer Diagnostics Product Specification

14.8.3 Almac Group Companion Cancer Diagnostics Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Chapter 15 Global Companion Cancer Diagnostics Market Forecast (2022-2027)

15.1 Global Companion Cancer Diagnostics Consumption Volume, Revenue and Price Forecast (2022-2027)

15.1.1 Global Companion Cancer Diagnostics Consumption Volume and Growth Rate Forecast (2022-2027)

15.1.2 Global Companion Cancer Diagnostics Value and Growth Rate Forecast (2022-2027)

15.2 Global Companion Cancer Diagnostics Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)

15.2.1 Global Companion Cancer Diagnostics Consumption Volume and Growth Rate Forecast by Regions (2022-2027)

15.2.2 Global Companion Cancer Diagnostics Value and Growth Rate Forecast by Regions (2022-2027)

15.2.3 North America Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.4 East Asia Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.5 Europe Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.6 South Asia Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.7 Southeast Asia Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.8 Middle East Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.9 Africa Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.10 Oceania Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.11 South America Companion Cancer Diagnostics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.3 Global Companion Cancer Diagnostics Consumption Volume, Revenue and Price Forecast by Type (2022-2027)

15.3.1 Global Companion Cancer Diagnostics Consumption Forecast by Type (2022-2027)

15.3.2 Global Companion Cancer Diagnostics Revenue Forecast by Type (2022-2027)

15.3.3 Global Companion Cancer Diagnostics Price Forecast by Type (2022-2027)

15.4 Global Companion Cancer Diagnostics Consumption Volume Forecast by Application (2022-2027)

15.5 Companion Cancer Diagnostics Market Forecast Under COVID-19

Chapter 16 Conclusions

Research Methodology